Conversion to sirolimus in pediatric renal transplantation recipients.

  title={Conversion to sirolimus in pediatric renal transplantation recipients.},
  author={Clotilde Druck Garcia and Viviane de Barros Bittencourt and Adriana Martins Barros Alves and V{\'a}lter Duro Garcia and Ana Cl{\'a}udia Tumelero and Jenny Antonello and Denise Maria Avancini Costa Malheiros},
  journal={Transplantation proceedings},
  volume={38 6},
We retrospectively evaluated the efficacy and safety of sirolimus (SRL) in 16 pediatric renal transplant recipients, who were 9.4 +/- 4.1 years of age when they first received SRL. The indications for SRL therapy were rescue from steroid-resistant acute rejection (31.3%), neoplasia (31.3%), diabetes (12.5%), polyomavirus-associated nephropathy (6.3%), chronic allograft dysfunction (6.3%), calcineurin inhibitor nephrotoxicity (6.3%), and hemolytic uremic syndrome (6.3%). Mean follow-up after the… CONTINUE READING